Arca
Skip to content
Tools
Tools

Liposarcoma

Drug research and approvals for liposarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 37 studies of liposarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 2 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 37
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 37 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 2

Phase 3 5

Phase 2 12 of 20

  • PazopanibMacrophage colony stimulating factor receptor inhibitor
  • RibociclibCyclin-dependent kinase 4 inhibitor
  • CabazitaxelTubulin inhibitor
  • PioglitazoneMyxoid liposarcoma · Peroxisome proliferator-activated receptor gamma agonist
  • RegorafenibTyrosine-protein kinase ABL inhibitor
  • BevacizumabVascular endothelial growth factor A inhibitor
  • DexamethasoneMyxoid liposarcoma · Glucocorticoid receptor agonist
  • IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
  • PalbociclibCDK6/cyclin D1 inhibitor
  • NivolumabProgrammed cell death protein 1 inhibitor
  • EfatutazonePeroxisome proliferator-activated receptor gamma agonist
  • RidaforolimusSerine/threonine-protein kinase mTOR inhibitor

Phase 1 or earlier 11

How its trials ended

136 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 37 whose ending is known, 24% met their primary endpoint, 14% missed it and 62% stopped early.

  • Ongoing5540%
  • Completed, result not reported3425%
  • Stopped: other or unclear1310%
  • Status unknown107%
  • Met its primary endpoint97%
  • Stopped: sponsor or business decision64%
  • Missed its primary endpoint54%
  • Stopped: lack of efficacy21%
  • Stopped: enrollment or feasibility21%

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 16, 2023A phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (bi 907828) treatment in patients with treatment-naïve…Brigimadlin (bi 907828)Boehringer Ingelheim (Canada) Ltd LteeClosed
Feb 11, 2022Brightline-1: a phase II/III, randomized, open-label, multi-center study of brigimadlin (bi 907828) compared to doxorubicin as first line treatment of patients…Brigimadlin (bi 907828)Boehringer Ingelheim (Canada) Ltd LteeClosed
Aug 20, 2021A randomized multicenter phase 3 study of milademetan versus trabectedin in patients with dedifferentiated liposarcomaMilademetan (RAIN-32)Rain OncologyClosed
Jul 30, 2019A phase 2 single arm open-label clinical trial of ADP-A2M4 spear t cells in subjects with advanced synovial sarcoma or myxoid/round cell liposarcoma (spearhead…ADP-A2M4Uswm CT, LLCOngoing
Nov 20, 2015A phase 2-3 multicenter, randomized, double-blind study of selinexor (KPT-330) versus placebo in patients with advanced unresectable dedifferentiated…Selinexor (KPT-330)Karyopharm TherapeuticsOngoing
Dec 22, 2014A phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcomaSiremadlin (HDM201)/ Ribociclib (LEE011)Novartis PharmaceuticalsClosed

FDA orphan designations

Approved first, then open designations, newest first
Jan 28, 2016HalavenTreatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimenEisai Inc.Approved
Oct 23, 2015YondelisFor the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing…Janssen Research & Development, LLCApproved
Mar 21, 2023N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo[d]imidazol-6-…Treatment of LiposarcomaShanghai Pharma Biotherapeutics USA Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.